Telbivudine
- Generic Name
- Telbivudine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C10H14N2O5
- CAS Number
- 3424-98-4
- Unique Ingredient Identifier
- 2OC4HKD3SF
- Background
Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects.
- Indication
For the treatment of chronic hepatitis B in adult and adolescent patients ≥16 years of age with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
- Associated Conditions
- Chronic Hepatitis B Infection
- Associated Therapies
- -
Renoprotective Effects of Telbivudine in Chronic Hepatitis B
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 31
- Registration Number
- NCT03778567
- Locations
- 🇭🇰
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
Renal Function Improvement in HBsAg Positive Kidney Transplantation Patients Under Telbivudine Treatment.
- Conditions
- Interventions
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT02894554
EFFORT Further Extension Study
- Conditions
- Interventions
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2016-07-07
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 130
- Registration Number
- NCT02826070
- Locations
- 🇨🇳
Beijing Ditan Hospital, Beijing, Beijing, China
🇨🇳People's Hospital of Beijing University, Beijing, Beijing, China
🇨🇳The Third Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
Tenofovir Versus Tenofovir + Telbivudine for Chronic Hepatitis B
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- Seng Gee Lim
- Target Recruit Count
- 146
- Registration Number
- NCT02774837
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in CHB
- First Posted Date
- 2015-11-26
- Last Posted Date
- 2015-11-26
- Target Recruit Count
- 450
- Registration Number
- NCT02615639
Replacement of Lamivudine by Telbivudine to Improve Renal Function
- Conditions
- Interventions
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT02447705
The Effect of Anti-viral Drugs Used in Late Pregnancy on Long-term Development of Children
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2014-11-26
- Lead Sponsor
- Beijing Ditan Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT02301650
Efficacy of Antiviral Therapy in Pregnancy in Preventing Vertical Transmission of HBV in Mothers With a High Viral Load
- Conditions
- Interventions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Beijing Ditan Hospital
- Target Recruit Count
- 600
- Registration Number
- NCT02253485
Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 53
- Registration Number
- NCT02058108
- Locations
- 🇺🇦
Novartis Investigative Site, Vinnytsia, Ukraine
Effect of Telbivudine on Renal Function and Proteinuria in Patients With CHB & Chronic Renal Diseases
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2016-07-28
- Lead Sponsor
- Chinese University of Hong Kong
- Registration Number
- NCT02049736
- Locations
- 🇭🇰
Cheng Suen Man Shook Hepatitis Center, Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, Hong Kong
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.